miR-155 as a Biomarker in B-Cell MalignanciesAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeMicroRNAs in B-cells: from normal differentiation to treatment of malignanciesIndividual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialThe myeloma stem cell concept, revisited: from phenomenology to operational termsC-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevanceIdentification of ID-1 as a potential target gene of MMSET in multiple myelomaReduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatmentGeneration of a predictive melphalan resistance index by drug screen of B-cell cancer cell linesProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma[The clinical research unit].Detection of illegitimate rearrangement within the immunoglobulin locus on 14q32.3 in B-cell malignancies using end-sequenced probes.Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.Magnetic resonance investigation of bone marrow following priming and stem cell mobilization.Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study.Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia.Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment.The cellular immune response after splenectomy in humans. Impaired immunoglobulin synthesis in vitro.[Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment]Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes.Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells.Clinical practice and future needs in recombinant human granulocyte colony-stimulating factor treatment: a review of randomized trials in clinical haemato-oncology.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.A model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells.Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease.The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysisThe clinical impact of vascular growth factors and endothelial progenitor cells in the acute coronary syndrome.Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition.Clinical application of dendritic cells in cancer vaccination therapy.Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisPromoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjectsImpact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaLong Noncoding RNA Expression during Human B-Cell DevelopmentMolecular and clinical follow-up after treatment of multiple myeloma.
P50
Q26746573-31D70524-EFBD-4B89-8296-A8421B54569AQ26782868-48F1FD6E-07C8-4C39-B5BC-1EBF19B7EB24Q26824682-B971D0A9-D631-4F2D-A37A-7D8EFB82ABA4Q27690791-A7CBAA9F-A56D-47CB-A524-BB4BA7EDFC33Q28075927-0DC7FE2A-6E2F-4517-97D6-A89C708B17BBQ28076070-865C436F-D60B-4BF9-8347-DE9D4A3D49D3Q28235799-F54E9E51-3E7B-4C30-9CA3-325073237458Q28268453-CBD7D283-BFF0-47E8-9468-3C4D9F38E103Q28378324-B5DD78CB-8E40-49C0-BE03-33D0E0B3504BQ28477988-71213359-6A55-45C1-A470-3BDD05DCFE64Q28537857-029C2214-6C7F-48F5-9CF5-C09AFE7B5FC6Q30388832-DC0BFAFB-746C-48FC-BA51-2BD6FA3CA64FQ30727143-FBB0DA4A-A320-4ABD-BB36-6B9468B9224CQ33193741-A14D60DD-47B6-4713-BD79-7758FF73112DQ33255102-33DB0794-E34F-4D44-B87E-E15FEDF33BCDQ33262618-F87B137F-BD12-4FCC-B3D4-31D8E376ACFFQ33340859-DF99C56F-2CB1-4205-A240-03183B407553Q33362760-80CB330B-BB5A-43A2-A927-358FEC21CE76Q33389387-C510EA3A-AB96-4EE2-A70F-A96567AEACE1Q33479820-51C77B7C-F2E9-487C-AEB9-2B914124A3C5Q33487725-21687D78-9489-409F-A502-F794CB290C31Q33590627-0DC65DAD-AF69-4B42-9873-89377FBADE34Q33695919-8B2FDE30-0B9B-4EB6-9FC8-F9916912F86DQ33756543-36C462DA-C50D-40E4-8924-893E8EC09C75Q33886244-AA75F45A-DEAD-4F25-BE08-B962C7CD5955Q34274265-08CFA4F9-6EE9-46DA-95B7-013BA2627E44Q34450381-486A113E-9E1E-4250-977C-3D7EB5038EA8Q34467490-0D5C08C0-8506-476D-BFDA-AF781D804C48Q34545357-F4275AF5-35E8-4F8D-8434-EF94217DED45Q34636362-B8E931EF-1BEF-474A-9A14-F405E277ADD9Q35023376-2C2B27D4-3AA1-4C39-A217-072101A39406Q35127033-547742B3-6D83-4658-BEDB-58482F54BEE5Q35182422-3B490B51-A519-44F4-8F77-C5937CAD0174Q35219339-EE20800A-CC39-4289-8998-EC4019F5262BQ35402899-1A54AF71-6E45-46B5-AE1C-A496BA5338C5Q35419876-AA8C9D2B-FC9D-44F0-BCDA-0A3407E96581Q35557987-6D3108B6-B1BC-408E-BD73-457BEEC64D44Q35730160-0DB3E425-08FD-42C9-ABEB-ECAFA46AA924Q35783785-1A2F81FD-D191-4989-876B-10BF131A0D91Q35792881-697CE2A7-23A8-401F-BB0A-C5191AB4E0A8
P50
description
hulumtues
@sq
klinisk professor på Aalborg Universitetshospital
@da
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Hans Erik Johnsen
@ast
Hans Erik Johnsen
@da
Hans Erik Johnsen
@en
Hans Erik Johnsen
@es
Hans Erik Johnsen
@nl
Hans Erik Johnsen
@sl
type
label
Hans Erik Johnsen
@ast
Hans Erik Johnsen
@da
Hans Erik Johnsen
@en
Hans Erik Johnsen
@es
Hans Erik Johnsen
@nl
Hans Erik Johnsen
@sl
prefLabel
Hans Erik Johnsen
@ast
Hans Erik Johnsen
@da
Hans Erik Johnsen
@en
Hans Erik Johnsen
@es
Hans Erik Johnsen
@nl
Hans Erik Johnsen
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0001-8253-2913
P735
P7859
lccn-n87811065